您好,欢迎您来到格朗瑞生物科技公司网站!
[登录]
[注册]
  • Content

Adipogen/anti-VEGFR-2 (human), mAb (EIC)/AG-20T-0108-C100/100 ?g

一抗
Adipogen/anti-VEGFR-2 (human), mAb (EIC)/AG-20T-0108-C100/100 ?g


商品编号


AG-20T-0108-C100



品牌


Adipogen



公司


Adipogen



公司分类


Antibodies



Size

100 ?g


商品信息


More Information



Product Details



Synonyms

Vascular Endothelial Growth Factor Receptor-2; KDR; FLK-1



Product Type

Monoclonal Antibody



Properties



Clone

EIC



Isotype

Mouse IgG1



Immunogen/Antigen

Recombinant human soluble extracellular VEGFR-2.



Application


ELISA
:
(1-5μg/ml)
Flow Cytometry
: (2-10μg/ml)
Immunohistochemistry
: (6-30μg/ml)
Western Blot:
(2-5μg/ml)
Optimal conditions must be determined individually for each application.



Crossreactivity

Human



Specificity

The antibody will detect native human VEGFR-2/KDR in
ELISA
experiments and on the surface of different human cell types.



Purity

Protein G purified.



Purity Detail

Protein G purified.



Formulation

Lyophilized.



Reconstitution

Centrifuge vial prior to opening. Reconstitute with sterile water to a concentration of 0.1-1.0mg/ml.



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 6 months after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Admi
NIST
ration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.


Product References

Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization: G. Nowak, et al.; Circulation
110
, 3699 (2004)


上一篇 MCLAB/CHAPSO/DCSO100/1 Ea  下一篇 MCLAB/CHAPS/DCPS101/1 Ea

产品货号:5388.0

5388.0 ¥
11至15个工作日送达